Cyclin and CDK Regulation

Cyclin-dependent kinases (CDKs) are the engines that drive progression through the cell cycle, and they are inert unless bound by their regulatory cyclin partners. Because cyclin levels oscillate and additional layers of control modulate CDK activity, the cell cycle advances as an ordered, tightly regulated series of transitions.

Definition

Cyclins are regulatory proteins whose levels rise and fall through the cell cycle and which activate cyclin-dependent kinases (CDKs); the cyclin-CDK complexes phosphorylate substrates that drive transitions between cell cycle phases, and their activity is regulated by cyclin abundance, activating and inhibitory phosphorylation, and CDK inhibitor proteins.

Scope

This entry covers the cyclin-CDK pairs that drive each cell cycle phase, the multiple mechanisms that regulate CDK activity, the role of CDK inhibitors, and how this machinery is the target of the checkpoint signals that arrest the cycle. It complements the entry on checkpoint kinases and the DNA damage response. It is a mechanistic reference entry, not clinical guidance.

Core questions

• How do cyclins and CDKs combine to drive cell cycle progression?
• What layers of regulation control CDK activity beyond cyclin binding?
• How do CDK inhibitors restrain or fine-tune the cycle?
• How do checkpoints act on this machinery to enforce arrest?

Key concepts

• Cyclin-dependent kinases (CDKs)
• Cyclins and their cyclic abundance
• Cyclin-CDK complexes for each phase
• Activating and inhibitory phosphorylation
• CDK inhibitors (INK4 and Cip/Kip families)
• Restriction point and G1/S commitment
• Deregulation of the cell cycle engine in cancer

Mechanisms

A CDK is catalytically inactive on its own and becomes active when bound by a cyclin, with full activity requiring additional control through activating and inhibitory phosphorylation (Morgan, 1995). Different cyclin-CDK pairs operate at successive phases, and their ordered activation, driven partly by the periodic synthesis and degradation of cyclins, produces the unidirectional progression of the cycle. CDK inhibitor proteins of the INK4 and Cip/Kip families further restrain or modulate activity, acting as both negative and, in some contexts, positive regulators of G1 progression (Sherr & Roberts, 1999). Checkpoint signals converge on this machinery, inhibiting cyclin-CDK activity to halt the cycle when damage is detected, which links cyclin-CDK regulation to the DNA damage response (Sherr, 1996; Malumbres & Barbacid, 2009).

Clinical relevance

Deregulation of cyclins, CDKs, and their inhibitors is a frequent feature of cancer, in which loss of normal restraint drives unscheduled proliferation, and the cyclin-CDK machinery is the conceptual basis for CDK-directed therapeutic strategies (Sherr, 1996; Malumbres & Barbacid, 2009). This entry describes mechanisms and is not a basis for individual treatment decisions.

Evidence & guidelines

The content reflects foundational and integrative reviews of cyclin-CDK regulation and its role in cancer (Morgan, 1995; Sherr & Roberts, 1999; Sherr, 1996; Malumbres & Barbacid, 2009). It is mechanistic reference material, not clinical practice guidance.

History

The discovery of cyclins as proteins that accumulate and are abruptly destroyed each cycle, together with the identification of the cyclin-dependent kinases they activate, revealed the engine that drives cell division. Subsequent work defined the regulatory phosphorylation and the CDK inhibitor families, and showed that disruption of this machinery is central to cancer (Morgan, 1995; Sherr, 1996; Sherr & Roberts, 1999).

Key figures

• David O. Morgan
• Charles J. Sherr
• James M. Roberts
• Marcos Malumbres
• Mariano Barbacid

Seminal works

• morgan-1995
• sherr-1996
• sherr-roberts-1999

Frequently asked questions

Why does a CDK need a cyclin?

A cyclin-dependent kinase is catalytically inactive by itself; binding a cyclin partner is required to activate it, so the periodic availability of cyclins helps time when each kinase acts.

What do CDK inhibitors do?

They are proteins that bind and restrain cyclin-CDK complexes, helping enforce arrest or fine-tune progression, and their loss can contribute to uncontrolled proliferation.